Regenerative medicine company Organogenesis Holdings (NASDAQ: ORGO) shares have jumped premarket after the company reported its preliminary third-quarter 2020 financial results shortly after the closing bell on Wednesday.
The company reported that it expects third-quarter revenue of between $99 and $100 million, up between 54% to 56% for the three months ending the 30th of September.
ORGO also said that the company expects to report a positive GAAP net income and a positive adjusted EBITDA for the period.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
The company also upgraded its full-year 2020 guidance. ORGO said that it now expects net revenue of between $311 to $314 million compared to the previously forecasted $261 million with its primary revenue driver being its advanced wound care products.
ORGO went on to state that it expects to report a positive GAAP net income and adjusted EBITDA for both the fourth quarter and the fiscal full-year period.
After-hours trading has seen the company’s stock price jump almost 39% higher to $5.25 per share after the previous days close at $3.78.
PEOPLE WHO READ THIS ALSO VIEWED:
- Rolls-Royce share price falls after pricing £2bn bond offer
- Trade stocks with eToro
- Learn stock trading strategies